An Open-Label Study of Xanomeline/Trospium Chloride for Schizophrenia
The purpose of this study is to evaluate a recently FDA-approved medication to treat schizophrenia. This study is for intended for people diagnosed with schizophrenia who are not able to tolerate or are not happy with their current antipsychotic treatment; in other words, they are still currently experiencing symptoms, experiencing side effects, or are not responding to their medication. There is no placebo in this study, so everyone will get treated with the study medication xanomeline/trospium chloride.
What will I do if I participate?
Participants will take part in 13 study visits in-person at Northwestern Hospital. Visits 1 and 2 are to evaluate potential participants’ eligibility to take part in the study. Visits 3-12 are also in-person and take place over 6 months and will involve receiving the study medication. The last visit is a brief follow-up visit.
Eligibility Criteria
- Open to ages 18-40.
- Diagnosed with Schizophrenia.
- Must be stable on antipsychotic for at least 6 weeks.